(November 7, 2017)
Quantitative Systems Pharmacology (QSP) is a mathematical modeling and engineering approach to translational medicine that aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. QSP approaches de-risk projects, accelerate the development of best in class therapeutics, and reduce late stage attrition rates. This results in helping industry save money, accelerate timelines, and make better therapeutics, ultimately improving patients’ lives.
In this webinar, two case studies will be discussed to highlight how QSP efforts in rheumatoid arthritis have accelerated the discovery and development of best-in-class therapeutics, and impacted critical decisions, in the continuum from preclinical exploration to clinical research. Specifically, we will show how QSP impacts:
- Biological understanding
- Lead generation
- Clinical candidate selection
- IND support
- Clinical trial go/no go decisions from industry
This webinar is ideal for scientists and decision makers in R&D who want to learn more about how to leverage QSP to provide quantitative guidance for their drug discovery and development.
John M. Burke, PhD
Co-Founder, President, and CEO
Dr. Burke’s BS and MS are in Applied Mathematics from the University of Massachusetts, Lowell, in 1993 and 1995, respectively. His PhD degree is in Applied Mathematics from Arizona State University in 2003. His research interests include singularly and randomly perturbed differential equations, bifurcation theory, and applying dynamical systems theory to study and understand how cells and tissues make decisions in humans, and human disease. Prior to co-founding Applied BioMath, Dr. Burke joined Boehringer Ingelheim in 2008 as Associate Director, Head of Systems Biology. In 2011, he was promoted to Senior Principal Scientist. At Boehringer Ingelheim, he started, developed and managed the Systems Biology group, portfolio, and strategy. The group was responsible for applying systems techniques to the drug discovery process across all Research sites, and supporting Development and Medicine. Prior to Boehringer Ingelheim, Dr. Burke was at Merrimack Pharmaceuticals, Co-Scientific Director of the Cell Decision Processes Center, Systems Biology Department, HMS, and was a Sr. Postdoctoral Fellow in Douglas A. Lauffenburger’s lab, Biological Engineering Department, MIT. While at MIT and HMS, Dr. Burke was an early leader as he provided Systems Biology and Pharmacology consulting or advising for various companies, including AstraZeneca, Pfizer, Momenta, and Matlab. Presently he is an on the advisory boards for the MIT “Human Physiome on a Chip” MIT-DARPA Program, and the Mathematics Department at the University of Massachusetts, Lowell, and he codeveloped and is presently co-lecturing a modeling and coding course at Harvard Medical School.